Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Cowen

Cowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $60.00 (from $45.00) while maintaining an Outperform rating.

The analyst commented, "BioHaven is executing on Nurtec's introduction, and despite the pandemic impact, the initial prescription figures for the first 6 weeks on market are already well ahead of our expectations. With what should be a continued successful acute indication launch, this is setting the stage for the broader and more differentiated prophylaxis indication, which is on track for a 2021 introduction. Add."

You May Also Be Interested In

• Shoe Station Group (SHOE) PT Lowered to $15 at Williams Trading
• H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)
• Brinker Int'l (EAT) PT Lowered to $240 at DA Davidson Ahead of Analyst Day